GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Sale Of Investment

CTOR (Citius Oncology) Sale Of Investment : $ Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Sale Of Investment?

Citius Oncology's sale of investment for the six months ended in Sep. 2024 was $0.00 Mil. It means Citius Oncology gained $0.00 Mil from selling investments.

Compared with last quarter ($0.00 Mil in Sep. 2023 ), Citius Oncology gained the same money from selling investments in Sep. 2024 ($0.00 Mil).


Citius Oncology Sale Of Investment Historical Data

The historical data trend for Citius Oncology's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Sale Of Investment Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Sale Of Investment
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Sale Of Investment - - -

Citius Oncology Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.


Citius Oncology Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.